US Patent Issued to SHANGHAI VITALGEN BIOPHARMA on Dec. 9 for "Recombinant AAV vectors for treating glutaric aciduria type I" (Chinese Inventors)

ALEXANDRIA, Va., Dec. 9 -- United States Patent no. 12,491,266, issued on Dec. 9, was assigned to SHANGHAI VITALGEN BIOPHARMA Co. LTD. (Shanghai).

"Recombinant AAV vectors for treating glutaric aciduria type I" was invented by Lu Guo (Beijing), Xi Zhu (Shanghai), Shin-Shay Tian (Shanghai) and Xiaoping Zhao (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to codon-optimized sequences coding for hGCDH polypeptide and recombinant adeno-associated virus (rAAV) vectors comprising one of said sequences under the control of a promoter component. Also provided herein are viral particles comprising the rAAV vector, a pharmaceutical composition comprising the rAAV vector or the v...